Information Provided By:
Fly News Breaks for April 4, 2019
Apr 4, 2019 | 14:56 EDT
Piper Jaffray analyst Edward Tenthoff maintains his Overweight rating and $3 price target on Aveo Pharmaceuticals after the company "opportunistically" raised $25M by issuing 21.7M shares at $1.15 per share and 21.7M in warrants with a $1.25 strike price. The analyst, who estimates that Aveo now holds pro forma cash of about $57M, said the primary driver for the stock remains the OS analysis for TIVO-3 that is scheduled to be reported in Q4. If the hazard ratio does not drop to less than 1.0 for tivozanib, Tenthoff does not believe the FDA will accept a new NDA filing, he noted.
News For AVEO From the Last 2 Days
There are no results for your query AVEO